LivaNova (NASDAQ:LIVN) Sets New 1-Year High – Here’s What Happened

LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high on Tuesday . The stock traded as high as $74.76 and last traded at $74.46, with a volume of 19139 shares changing hands. The stock had previously closed at $73.64.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Weiss Ratings upgraded shares of LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a report on Thursday, May 7th. Mizuho upped their price objective on shares of LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Robert W. Baird decreased their target price on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Piper Sandler reissued an “overweight” rating and set a $85.00 target price on shares of LivaNova in a research report on Thursday, February 19th. Finally, Needham & Company LLC boosted their target price on shares of LivaNova from $64.00 to $81.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, LivaNova has a consensus rating of “Moderate Buy” and an average price target of $79.38.

LivaNova Trading Up 1.3%

The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The firm’s 50-day moving average price is $65.57 and its 200 day moving average price is $63.71. The company has a market capitalization of $4.11 billion, a P/E ratio of 38.34 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last posted its earnings results on Wednesday, May 6th. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.85 by $0.13. The company had revenue of $362.26 million during the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s revenue for the quarter was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, equities research analysts predict that LivaNova PLC will post 3.72 earnings per share for the current year.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in LivaNova by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock worth $1,394,000 after purchasing an additional 1,360 shares in the last quarter. Goldman Sachs Group Inc. grew its position in LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after purchasing an additional 36,094 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after purchasing an additional 15,405 shares in the last quarter. Intech Investment Management LLC grew its position in LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock worth $1,724,000 after purchasing an additional 7,195 shares in the last quarter. Finally, Strs Ohio bought a new stake in LivaNova in the 1st quarter worth about $130,000. 97.64% of the stock is owned by institutional investors.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.